Cronos Company Leadership
| CRON Stock | USD 2.56 0.02 0.78% |
Cronos employs about 459 people. The company is managed by 13 executives with a total tenure of roughly 9 years, averaging almost 0.0 years of service per executive, having 35.31 employees per reported executive. Analysis of Cronos' management performance can provide insight into the firm performance.
Cronos Management Team Effectiveness
The company has return on total asset (ROA) of (0.0139) % which means that it has lost $0.0139 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0367 %, meaning that it created $0.0367 on every $100 dollars invested by stockholders. Cronos' management efficiency ratios could be used to measure how well Cronos manages its routine affairs as well as how well it operates its assets and liabilities.Cronos holds a total of 382.89 Million outstanding shares. Cronos Group retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Some institutional investors establish a significant position in stocks such as Cronos in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Cronos, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
Cronos Workforce Comparison
Cronos Group is rated fourth in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 6,786. Cronos holds roughly 459 in number of employees claiming about 7% of equities under Health Care industry.
The company has Profit Margin (PM) of 0.27 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of (0.14) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.14. Cronos Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Cronos insiders, such as employees or executives, is commonly permitted as long as it does not rely on Cronos' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Cronos insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Arye Weigensberg over a month ago Acquisition by Arye Weigensberg of 6423 shares of Cronos subject to Rule 16b-3 | ||
Shannon Buggy over three months ago Disposition of 9709 shares by Shannon Buggy of Cronos at 1.99 subject to Rule 16b-3 | ||
Jeffrey Jacobson over three months ago Acquisition by Jeffrey Jacobson of 195538 shares of Cronos subject to Rule 16b-3 | ||
Doucet Terrence Gregory Joseph over six months ago Disposition of 23897 shares by Doucet Terrence Gregory Joseph of Cronos subject to Rule 16b-3 | ||
Arye Weigensberg over six months ago Acquisition by Arye Weigensberg of 21482 shares of Cronos subject to Rule 16b-3 | ||
Adam Wagner over six months ago Acquisition by Adam Wagner of 6276 shares of Cronos subject to Rule 16b-3 | ||
Gorenstein Michael Ryan over six months ago Disposition of 31361 shares by Gorenstein Michael Ryan of Cronos subject to Rule 16b-3 | ||
Gorenstein Michael Ryan over six months ago Disposition of 327801 shares by Gorenstein Michael Ryan of Cronos subject to Rule 16b-3 |
Cronos Notable Stakeholders
A Cronos stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Cronos often face trade-offs trying to please all of them. Cronos' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Cronos' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Michael JD | CEO President | Profile | |
| Jeffrey Jacobson | Vice President - Business Development | Profile | |
| Lloyd Wilson | VP Officer | Profile | |
| James III | Controller VP | Profile | |
| Shayne Laidlaw | Director Strategy | Profile | |
| Terry Doucet | General Secretary | Profile | |
| Kevin Gifford | VP Fin | Profile | |
| James Holm | Executive Officer | Profile | |
| Anna Shlimak | Senior Strategy | Profile | |
| Carlos Cortez | Controller VP | Profile | |
| Arye Weigensberg | Senior Development | Profile | |
| Shannon Buggy | Senior People | Profile | |
| Adam Wagner | General Israel | Profile |
About Cronos Management Performance
The success or failure of an entity such as Cronos Group often depends on how effective the management is. Cronos management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Cronos management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Cronos management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
It manufactures, markets, and distributes hemp-derived supplements and cosmetic products through e-commerce, retail, and hospitality partner channels under the Lord Jones and Happy Dance brands in the United States. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada. Cronos operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 626 people.
Cronos Workforce Analysis
Traditionally, organizations such as Cronos use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Cronos within its industry.Cronos Manpower Efficiency
Return on Cronos Manpower
| Revenue Per Employee | 256.2K | |
| Revenue Per Executive | 9M | |
| Net Income Per Employee | 87.2K | |
| Net Income Per Executive | 3.1M | |
| Working Capital Per Employee | 1.9M | |
| Working Capital Per Executive | 68.2M |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cronos Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Will Pharmaceuticals sector continue expanding? Could Cronos diversify its offerings? Factors like these will boost the valuation of Cronos. Projected growth potential of Cronos fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Cronos data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Investors evaluate Cronos Group using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Cronos' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Cronos' market price to deviate significantly from intrinsic value.
It's important to distinguish between Cronos' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Cronos should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Cronos' market price signifies the transaction level at which participants voluntarily complete trades.